WGGeneDx WGS · NASDAQ
$71.02 +9.79% (+$6.33)
- Market cap
- $2.12B
- Enterprise value
- $2.23B
- P/E
- -
- Forward P/E
- 786.7x
- PEG
- -
- P/S
- 4.7x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -14.8%
- Gross margin
- 68.2%
- Net margin
- -23.4%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.97
- Free float
- 96.9%
About the company
GeneDx is a biotechnology company specializing in genomic testing, particularly exome and genome sequencing, aimed at diagnosing rare and ultra-rare genetic disorders. Founded in 2000, the company is headquartered in Gaithersburg, Maryland. In 2021, GeneDx merged with Sema4 Holdings, strengthening its position in genomic testing. In 2024, the company achieved a significant financial turnaround, reporting its first adjusted net income in the third quarter and a year-over-year revenue increase of 52% to $76.6 million. GeneDx's shares are traded on NASDAQ under the symbol WGS.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Katherine A. Stueland
Employees
1,300
Headquarters
Stamford
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 22% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 13% this fiscal year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number